Analysis of response and acquired resistance to EGFR-TKI by multiple circulating tumor DNA with cancer-specific gene mutations
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000028990
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients judged by the investigator to be unsuitable for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie EGFR-TKI resistance in non-small cell lung cancer with circulating tumor DNA analysis?
How does the efficacy of EGFR-TKIs compare to standard-of-care treatments in non-small cell lung cancer patients with specific gene mutations?
Which cancer-specific gene mutations serve as predictive biomarkers for response to EGFR-TKIs in non-small cell lung cancer?
What are the common adverse events associated with EGFR-TKI therapy in non-small cell lung cancer and how are they managed?
Are there combination therapies or alternative drugs that overcome EGFR-TKI resistance in non-small cell lung cancer patients with acquired mutations?